Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Negrier

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Cancer Biotherapy|January 1, 1993
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaP A Palmer, J Atzpodien, T Philip, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
Pediatric Hematology and Oncology|January 1, 1990
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantationM C Favrot, J Michon, D Floret, et al.
Bone Marrow Transplantation|September 1, 1989
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantationM C Favrot, D Floret, S Negrier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
The New England Journal of Medicine|May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'ImmunothérapieS Negrier, B Escudier, C Lasset, et al.
Oncogene|September 13, 2011
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokinesR Grepin, M Guyot, M Jacquin, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancerM S Negrier, C N Pourreau, P A Palmer, et al.
British Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Cancer Biotherapy|January 1, 1993
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaP A Palmer, J Atzpodien, T Philip, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
Pediatric Hematology and Oncology|January 1, 1990
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantationM C Favrot, J Michon, D Floret, et al.
Bone Marrow Transplantation|September 1, 1989
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantationM C Favrot, D Floret, S Negrier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
The New England Journal of Medicine|May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'ImmunothérapieS Negrier, B Escudier, C Lasset, et al.
Oncogene|September 13, 2011
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokinesR Grepin, M Guyot, M Jacquin, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancerM S Negrier, C N Pourreau, P A Palmer, et al.
British Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.
Pageof 5